Investors focused on the Consumer Staples space have likely heard of Darling Ingredients (DAR), but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Consumer Staples peers, we might be able to answer that question.Darling Ingredients is a member of the Consumer Staples sector. This group includes 186 individual stocks and currently holds a Zacks Sector Rank of #10. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. DAR is currently sporting a Zacks Rank of #1 (Strong Buy).The Zacks Consensus Estimate for DAR's full-year earnings has moved 31.60% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.Based on the most recent data, DAR has returned 27.55% so far this year. Meanwhile, stocks in the Consumer Staples group have gained about 5.19% on average. This means that Darling Ingredients is performing better than its sector in terms of year-to-date returns.Looking more specifically, DAR belongs to the Food - Miscellaneous industry, a group that includes 47 individual stocks and currently sits at #180 in the Zacks Industry Rank. Stocks in this group have gained about 2.80% so far this year, so DAR is performing better this group in terms of year-to-date returns.Going forward, investors interested in Consumer Staples stocks should continue to pay close attention to DAR as it looks to continue its solid performance. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Darling Ingredients Inc. (DAR): Free Stock Analysis Report To read this article on Zacks.com click here.